Serina Therapeutics Inc Asset Resilience Ratio
Serina Therapeutics Inc asset resilience ratio. Serina Therapeutics Inc (SER) has an Asset Resilience Ratio of 83.31% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Serina Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Serina Therapeutics Inc (2021–2024)
Asset resilience ratio of Serina Therapeutics Inc from 2021 to 2024. This chart shows how Serina Therapeutics Inc's Asset Resilience Ratio has changed over time. Read how much debt does Serina Therapeutics Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Serina Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SER asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $8.62 Million | 69.44% |
| Short-term Investments | $1.72 Million | 13.86% |
| Total Liquid Assets | $10.34 Million | 83.31% |
Asset Resilience Insights
- Very High Liquidity: Serina Therapeutics Inc maintains exceptional liquid asset reserves at 83.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Serina Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Serina Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Serina Therapeutics Inc Asset Resilience Ratio by Year (2021–2024)
Serina Therapeutics Inc asset resilience ratio by year from 2021 to 2024. The table below shows the annual Asset Resilience Ratio data for Serina Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 54.61% | $3.67 Million | $6.72 Million | +50.76pp |
| 2023-12-31 | 3.85% | $345.00K | $8.97 Million | -16.05pp |
| 2022-12-31 | 19.90% | $645.00K | $3.24 Million | -11.69pp |
| 2021-12-31 | 31.59% | $996.45K | $3.15 Million | -- |
About Serina Therapeutics Inc
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more